NCT00466986View on ClinicalTrials.gov

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions

Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Abraxane

Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days

Trial Locations (1)

30342

Southeastern Gynecologic Oncology, Atlanta

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Southeastern Gynecologic Oncology

OTHER